Modality
ERT
MOA
PCSK9i
Target
BCMA
Pathway
Amyloid
MCLCervical CaAngelman
Development Pipeline
Preclinical
May 2017
→ Jan 2026
PreclinicalCurrent
NCT06532619
858 pts·Cervical Ca
2017-05→2026-01·Completed
858 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-212mo agoInterim· Cervical Ca
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Preclinical
Complet…
Catalysts
Interim
2026-01-21 · 2mo ago
Cervical Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06532619 | Preclinical | Cervical Ca | Completed | 858 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |